Amyloidosis of the Heart and Kidney
References
- Benson MD, Buxbaum JN, Eisenberg DS, et al. Amyloid nomenclature 2018: recommendations by the International Society of Amyloidosis (ISA) nomenclature committee. Amyloid. 2018 Dec;25(4):215–219. doi: 10.1080/13506129.2018.1549825
- Sperry BW, Reyes BA, Ikram A, et al. Tenosynovial and Cardiac Amyloidosis in Patients Undergoing Carpal Tunnel Release. J Am Coll Cardiol. 2018 Oct 23;72(17):2040–2050. doi: 10.1016/j.jacc.2018.07.092
- Nakagawa M, Sekijima Y, Yazaki M, et al. Carpal tunnel syndrome: a common initial symptom of systemic wild-type ATTR (ATTRwt) amyloidosis. Amyloid. 2016;23(1):58–63. doi: 10.3109/13506129.2015.1135792
- McCausland KL, White MK, Guthrie SD, et al. Light Chain (AL) Amyloidosis: The Journey to Diagnosis. 2018 Apr;11(2):207–216. doi: 10.1007/s40271-017-0273-5
- Kyle RA, Larson DR, Kurtin PJ, et al. Incidence of AL Amyloidosis in Olmsted County, Minnesota, 1990 through 2015. Mayo Clin Proc. 2019 Mar;94(3):465–471. doi: 10.1016/j.mayocp.2018.08.041
- Quock TP, Yan T, Chang E, Guthrie S, Broder MS. Epidemiology of AL amyloidosis: a real-world study using US claims data. Blood Adv. 2018 May 22;2(10):1046–1053. doi: 10.1182/bloodadvances.2018016402
- Schmidt HH, Waddington-Cruz M, Botteman MF, et al. Estimating the global prevalence of transthyretin familial amyloid polyneuropathy. Muscle Nerve. 2018 May;57(5):829–837. doi: 10.1002/mus.26034
- González-López E, Gallego-Delgado M, Guzz-Merrelo G, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J. 2015 Oct 7;36(38):2585–94. doi: 10.1093/eurheartj/ehv338
- Castaño A, Narotsky DL, Hamid M, et al. Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Eur Heart J. 2017 Oct 7;38(38):2879–2887. doi: 10.1093/eurheartj/ehx350
- Tanskanen M, Peuralinna T, Polvikoski T, et al. Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study. Ann Med. 2008;40(3):232–9. doi: 10.1080/07853890701842988
- Muchtar E, Dispenzieri A, Lacy MQ, et al. Overuse of organ biopsies in immunoglobulin light chain amyloidosis (AL): the consequence of failure of early recognition. Ann Med. 2017 Nov;49(7):545–551. doi: 10.1080/07853890.2017.1304649
- Eirin A, Irazabal MV, Gertz MA, et al. Clinical features of patients with immunoglobulin light chain amyloidosis (AL) with vascular-limited deposition in the kidney. Nephrol Dial Transplant. 2012 Mar;27(3):1097–101. doi: 10.1093/ndt/gfr381
- Dispenzieri A, Gertz MA, Kumar SK, et al. High sensitivity cardiac troponin T in patients with immunoglobulin light chain amyloidosis. Heart. 2014 Mar;100(5):383–8. doi: 10.1136/heartjnl-2013-304957
- Gertz MA, Comenzo R, Falk RH, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol. 2005 Aug;79(4):319–28. doi: 10.1002/ajh.20381
- Dasari S, Theis JD, Vrana JA, et al. Amyloid Typing by Mass Spectrometry in Clinical Practice: a Comprehensive Review of 16,175 Samples. Mayo Clin Proc. 2020 Sep;95(9):1852–1864. doi: 10.1016/j.mayocp.2020.06.029
- Vrana JA, Gamez JD, Madden BJ, Theis JD, Bergen HR
3rd , Dogan A. Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood. 2009 Dec 3;114(24):4957–9. doi: 10.1182/blood-2009-07-230722 - Rezk T, Gilbertson JA, Mangione PP, et al. The complementary role of histology and proteomics for diagnosis and typing of systemic amyloidosis. J Pathol Clin Res. 2019 Jul;5(3):145–153. doi: 10.1002/cjp2.126
- Kourelis TV, Kyle RA, Dingli D, et al. Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis: The Mayo Clinic Experience. Mayo Clin Proc. 2017 Jun;92(6):908–917. doi: 10.1016/j.mayocp.2017.02.016
- Kumar S, Dispenzieri A, Lacy MQ, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol. 2012 Mar 20;30(9):989–95. doi: 10.1200/JCO.2011.38.5724
- Muchtar E, Dispenzieri A, Gertz MA, et al. Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 Update. Mayo Clin Proc. 2021 Jun;96(6):1546–1577. doi: 10.1016/j.mayocp.2021.03.012
- Palladini G, Hegenbart U, Milani P, et al. A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. Blood. 2014 Oct 9;124(15):2325–32. doi: 10.1182/blood-2014-04-570010
- Gertz MA, Falk RH, Skinner M, Cohen AS, Kyle RA. Worsening of congestive heart failure in amyloid heart disease treated by calcium channel-blocking agents. Am J Cardiol. 1985 Jun 1;55(13 Pt 1):1645. doi: 10.1016/0002-9149(85)90995-6
- Sayed RH, Rogers D, Khan F, et al. A study of implanted cardiac rhythm recorders in advanced cardiac AL amyloidosis. Eur Heart J. 2015 May 7;36(18):1098–105. doi: 10.1093/eurheartj/ehu506
- Kristen V, Dengler TJ, Hegenbart U, et al. Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death. Heart Rhythm. 2008 Feb;5(2):235–40. doi: 10.1016/j.hrthm.2007.10.016
- Singer W, Sandroni P, Opfer-Gehrking TF, et al. Pyridostigmine treatment trial in neurogenic orthostatic hypotension. Arch Neurol. 2006 Apr;63(4):513–8. doi: 10.1001/archneur.63.4.noc50340
- Ward JE, Ren R, Toraldo G, et al. Doxycycline reduces fibril formation in a transgenic mouse model of AL amyloidosis. Blood. 2011 Dec 15;118(25):6610–7. doi: 10.1182/blood-2011-04-351643
- Wechalekar AD, Whelan C. Encouraging impact of doxycycline on early mortality in cardiac light chain (AL) amyloidosis. Blood Cancer J. 2017 Mar 24;7(3):
e546 . doi: 10.1038/bcj.2017.26 - Trachtenberg BH, Kamble RT, Rice L, et al. Delayed autologous stem cell transplantation following cardiac transplantation experience in patients with cardiac amyloidosis. Am J Transplant. 2019 Oct;19(10):2900–2909. doi: 10.1111/ajt.15487
- Angel-Korman A, Stern L, Sarosiek S, et al. Long-term outcome of kidney transplantation in AL amyloidosis. Kidney Int. 2019 Sep;96(3):796. doi: 10.1016/j.kint.2019.06.001
- Heybeli C, Bentall A, Wen J, et al. A study from The Mayo Clinic evaluated long-term outcomes of kidney transplantation in patients with immunoglobulin light chain amyloidosis. Kidney Int. 2021 Mar;99(3):707–715. doi: 10.1016/j.kint.2020.06.036
DOI: https://doi.org/10.14797/mdcvj.1150 | Journal eISSN: 1947-6108
Language: English
Page range: 27 - 33
Submitted on: Jun 27, 2022
Accepted on: Aug 1, 2022
Published on: Sep 6, 2022
Published by: Houston Methodist DeBakey Heart & Vascular Center
In partnership with: Paradigm Publishing Services
Keywords:
© 2022 Horacio E. Adrogue, published by Houston Methodist DeBakey Heart & Vascular Center
This work is licensed under the Creative Commons Attribution-NonCommercial 4.0 License.